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Abstract
Background: Adverse events (AEs) are patient injuries caused by medical care. Previous studies
have reported increased mortality rates and prolonged hospital length of stay in patients having an
AE. However, these studies have not adequately accounted for potential biases which might
influence these associations. We performed this study to measure the independent influence of
intensive care unit (ICU) based AEs on in-hospital mortality and hospital length of stay.
Methods: Prospective cohort study in an academic tertiary-care ICU. Patients were monitored
daily for adverse clinical occurrences. Data about adverse clinical occurrences were reviewed by a
multidisciplinary team who rated whether they were AEs and whether they were preventable. We
determined the association of AEs in the ICU with time to death and time to hospital discharge
using multivariable survival analysis models.
Results: We evaluated 207 critically ill patients (81% required mechanical ventilation, median
Glasgow Coma Scale = 8, median predicted mortality = 31%). Observed mortality rate and hospital
length of stay were 25% (95% CI 19%–31%) and 15 days (IQR 8–34 days), respectively. ICU-based
AEs and preventable AEs occurred in 40 patients (19%, 95% CI 15%–25%) and 21 patients (10%,
95% CI 7%–15%), respectively. ICU-based AEs and preventable AEs were not significantly
associated with time to in-hospital death (HR = 0.93, 95% CI 0.44–1.98 and HR = 0.72 95% CI 0.25–
2.04, respectively). ICU-based AEs and preventable AEs were independently associated with time
to hospital discharge ((HR = 0.50, 95% CI 0.31–0.81 and HR = 0.46 95% CI 0.23–0.91,
respectively)). ICU-based AEs were associated with an average increase in hospital length of stay
of 31 days.
Conclusion: The impact of AEs on hospital length of stay was clinically relevant. Larger studies are
needed to conclusively measure the association between preventable AEs and patient outcomes.
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Background
Adverse events (AEs) refer to patient injuries caused by
medical care [1]. Widely quoted estimates of the mortality
attributable to medical error (44,000 to 98-000 deaths per
year in US hospitals [1]) are based on retrospective studies
that utilize chart reviews [2,3]. These studies measured AE
rates along with the proportion of AE patients who died.
This methodology does not adequately assess the causal
relationship between AEs and subsequent hospital out-
comes [4].
There are two reasons why chart reviews could lead to
flawed measures of how AEs impact patient outcomes.
First, the reviewer who determines AE status knows the
patient's outcome. This knowledge biases the assessment
of whether an AE (or error) actually occurred, as well as
the extent to which the AE contributed to the bad out-
come [5]. Second, acutely ill patients have substantial
risks of both poor outcomes and AEs. Thus, the associa-
tion of AEs with poor outcomes may be due to confound-
ing [4]. An example of this phenomenon is nicely
illustrated in a recent secondary analysis of data from a
randomized controlled trial showing that patients who
received incorrect doses of a study drug were more likely
to experience adverse clinical outcomes, irrespective of
whether the treatment received was placebo or the active
agent [6].
Determining the true burden attributable to AEs is impor-
tant for two reasons. First, policy makers and clinicians
require an accurate measure of the influence AEs have on
patient outcomes to gauge their importance. Second,
safety strategies need to target the most frequent and clin-
ically important AEs for the most efficient use of
resources. We therefore undertook a prospective study to
accurately quantify the effect of all AEs and preventable
AEs on hospital mortality and length of stay for a cohort
of intensive care unit (ICU) patients. We studied this pop-
ulation because ICU patients have well developed risk
adjustment instruments and a sufficiently high rate of AEs
and death to facilitate identifying an association between
AEs and outcomes.
Methods
For three consecutive months in 2006, we prospectively
followed all patients admitted to the ICU at the Ottawa
Hospital's Civic Campus from ICU admission until hospi-
tal discharge or death. Patient observation was censored
60 days after discharge from the ICU. The Ottawa Hospi-
tal Civic Campus is a tertiary care academic hospital pro-
viding a range of clinical services to the people of Eastern
Ontario, including a regional trauma service. The Ottawa
Hospital Research Ethics Board approved the protocol.
Baseline Data Collection
We collected baseline information on each patient when
they were admitted to the ICU and 24 hours later. This
information included basic demographic data, indication
for ICU admission, clinical information (including the
patient's baseline chronic illnesses), and physiologic
information to calculate each patient's predicted risk of
in-hospital death using the New Simplified Acute Physiol-
ogy Score [7]. This score is a validated method of predict-
ing in-hospital mortality for surgical and medical ICU
patients [8,9].
Identifying Adverse Clinical Occurrences
We used two steps to detect adverse events. First, we per-
formed active surveillance for adverse clinical occurrences,
which we defined as any incident in which there was an
undesirable change in patient status. These included: the
development of new significant laboratory findings (for
example, a drop in haemoglobin by more than 20%);
orders for medications that could indicate an AE (for
example, naloxone); an important change in the patient's
status (for example, the development of a new fever); the
diagnosis of specific conditions (such as deep vein throm-
bosis, ventilator associated pneumonia, or central line
associated blood stream infection); and the occurrence of
specific system events (such as a perceived inability to
obtain consultation in a timely manner, or an IV pump
error). These criteria were modified from those used in a
previous ICU-based patient safety study [10]. Additional
file 1 lists all criteria used to define adverse clinical occur-
rences in the study.
An ICU nurse (not directly involved in patient care but
working for the study alone) monitored patients for
adverse clinical occurrences while they remained in the
ICU. Surveillance occurred Mondays through Fridays
from 7:30 am until 3:30 pm and consisted of several activ-
ities. First, the nurse attended morning rounds with the
clinical team. Second, the nurse also remained in the ICU
throughout the day. During these times, she interacted
with all ICU staff, including nurses, physicians, pharma-
cists, respiratory therapists, and clerks. These interactions
included questions pertaining to the practitioners' knowl-
edge of any potential adverse clinical occurrences or the
spontaneous volunteering of such information. Finally,
the nurse reviewed all patient records for patients admit-
ted to the ICU each day.
Adverse clinical occurrences that occurred in the ICU out-
side of the hours of direct observation were identified in
several ways. Usually, they were discussed openly at
rounds on the subsequent day. In addition, providers
would often volunteer information. Finally, we relied to a
certain extent upon documentation in the medical record.BMC Health Services Research 2008, 8:259 http://www.biomedcentral.com/1472-6963/8/259
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We did not monitor patients for adverse occurrences after
they left the ICU.
The nurse recorded specific information about each
adverse clinical occurrence. This included: a detailed
description of the occurrence; all treatments the patient
was receiving at the time of the occurrence; the health
team's reaction to the occurrence; the patient's response to
this reaction; and the documented cause of the occur-
rence. The nurse obtained this information by reviewing
the medical record and interviewing relevant nurse(s), res-
ident physician(s), and attending intensivist physician(s).
We used a peer review process to determine whether the
adverse clinical occurrence was an adverse event. This proc-
ess was used to discriminate between occurrences that
were due to the patient's underlying condition versus
those that were a result of medical care. We used an
implicit review process as developed by Brennan and col-
leagues [11] and used by other investigators [2,3,12-15].
We adapted this method so that all AEs could be reviewed
by a multidisciplinary panel, as was done in previous
studies [10,16]. Each week during the study, a multi-disci-
plinary panel reviewed all adverse clinical occurrences
from the preceding seven days. The panel consisted of one
of the intensivist physicians involved in patient care for
the ICU that week, an ICU nurse, the nurse observer, and
a hospital-based internist (AJF). Note the intensivist was
not the physician of record but was the back up physician
for the week and the nurse was not directly involved in
any patient care responsibilities. Thus, they were not con-
flicted in terms of their propensity to rate cases as errors.
However, their direct knowledge of the cases allowed
them to make more informed ratings. For each adverse
clinical occurrence, the review panel determined whether
the occurrence was truly an event in which the patient's
status changed. If so, the panel rated whether treatment
was the cause of the occurrence versus the underlying dis-
ease process. If the panel judged that the occurrence was
due to treatment, the occurrence was classified as an
adverse event. All AEs were reviewed by the panel to deter-
mine if they were avoidable with the available resources
and currently accepted practices. If so, the event was clas-
sified as a preventable adverse event.
Study outcomes
The primary outcome was time to in-hospital death. The sec-
ondary outcome was time from ICU admission to hospital
discharge. These outcomes were measured by clinical chart
review and were done independently of AE ascertainment.
Statistical analysis
All analyses were conducted using SAS v9.1.3 (Cary,
N.C.). We described patient characteristics and propor-
tion of patients with AEs. For all proportions, we calcu-
lated 95% confidence limits using the Wilson Score
method. The incidence AE rate was calculated as the
number of AEs per ICU patient days. We compared char-
acteristics of patients who did and did not experience an
AE using the Wilcoxon Rank Sum Test for continuous var-
iables and the chi-square statistic for categorical variables.
We determined whether AEs were associated with time to
in-hospital death or time to hospital discharge using Cox
proportional hazards modelling. In all models, AE status
was expressed as a time-dependent covariate. We gener-
ated two models for each outcome. Model 1 included
'time to first AE' as its independent variable of interest.
Model 2 included 'time to first preventable AE' and 'time
to first non-preventable AE' as the independent variables
of interest. To determine whether Model 2 was more
informative than Model 1, we performed a likelihood
ratio test. The result of this test was non-significant for
both outcomes. For the time to death analyses, we cen-
sored patient observation at hospital discharge for
patients discharged alive. For the time to hospital dis-
charge analyses, we censored patient observation at death.
All models included the following covariates: age; proba-
bility of death calculated using the New Simplified Acute
Physiology Score; number of days in hospital prior to ICU
admission; and Charlson score to quantify chronic
comorbidities. The New Simplified Acute Physiology
Score is a validated method for predicting the probability
of in-hospital mortality. In our model, we estimate the
change in risk associated with a 10% increase in the prob-
ability of death. We stratified each model according to the
patient location immediately prior to ICU admission (i.e.,
emergency department, operating room, general ward).
The association between AE occurrence and the outcomes
of interest were reported as hazard ratios (i.e., the ratio of
risk for the outcome in patients with an AE vs. those with-
out an AE). For the time to hospital discharge analysis, a
hazard ratio less than one indicates that the probability of
discharge at any time is less in patients with an AE.
To identify the impact of AEs on hospital length of stay,
we generated and compared three survival curves. Using
the Kaplan Meier method, we first plotted unadjusted sur-
vival curves of the proportion of patients remaining in
hospital alive versus days in hospital for patients with and
without adverse events. Then, using the BASELINE STATE-
MENT in PROC PHREG, we generated an adjusted sur-
vival function using our Cox model for adverse event
patients under the condition that an adverse event never
occurred. Finally, to calculate the impact of adverse events
on length of stay, we compared the median length of stay
for each of these curves.BMC Health Services Research 2008, 8:259 http://www.biomedcentral.com/1472-6963/8/259
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Results
Table 1 describes the 207 patients in the study. Patients
were predominantly male, elderly, and most had been
admitted from a surgical service primarily directly from
the Emergency Department or the Operating Room. The
patient population was very ill: 81% of patients required
mechanical ventilation in the first 24 hours following ICU
admission; 50% of patients had a Glasgow Coma Scale
less than 8; and the median predicted mortality was 31%.
Table 2 and Additional file 1 (Appendix 2) describe each
AE. During a median ICU length of stay of 5 days (IQR 2–
10 days), 56 AEs occurred in 40 patients (19% [95% CI
15%–25%]). The 56 AEs consisted of 7 different types
with the most common being procedural complications
(n = 18 (32%)), nosocomial infections (n = 13 (23%)),
and adverse drug events (n = 12 (21%)). The median time
from ICU admission to AE was 3.5 days (IQR = 1–8.5
days). The panel deemed 23 AEs occurring in 21 patients
as preventable (10% [95% CI 7%–15%]). The 23 prevent-
able AEs consisted of five different AE types with the most
common being nosocomial infections (n = 8 (35%)),
therapeutic errors (n = 5 (22%)) and procedural compli-
cations (n = 6 (26%)).
Fifty-two patients died during the hospitalization (25%,
95% CI = 20%–31%) with a median time from ICU
admission to death of 9 days (IQR = 2.5–15 days). Thirty-
six patients died while in the ICU, the remainder dying on
a hospital ward after discharge from ICU. For patients dis-
charged alive, the median length of hospital stay after ICU
admission was 15 days (IQR = 8–34 days). Twelve
patients were still alive in hospital at the time of study
completion.
Patient characteristics were not associated with AE occur-
rence. Table 3 shows that none of the patient characteris-
tics differed significantly between those with or without
an AE. None of these patient characteristics were associ-
ated with time to AE in the survival model.
AEs were not associated with time to in-hospital death,
either before or after adjusting for factors also associated
with hospital mortality (Table 4a). The hazard ratio,
which measures the daily risk of death for patients with vs.
without AEs, was 0.93 (95% CI: 0.44–1.98). For prevent-
able AEs, there was a trend towards decreased risk of death
(HR = 0.72 (95%CI: 0.25–2.04)).
AEs were strongly associated with time to hospital dis-
charge, even after adjusting for other important clinical
factors (Table 4b). The hazard ratio, which measures the
daily risk of hospital discharge for patients with vs. with-
out AEs, was 0.50 (95% CI: 0.31–0.81).
Figure 1 illustrates the impact of AEs on length of stay. The
unadjusted median lengths-of-stay for patients with and
without AEs were 19 and 52 days, respectively. Our model
based estimate of the median length of stay in AE patients
under the condition that they did not have an AE was 21
days. Thus, experiencing an AE in the ICU appears to
translate to an average increase in the length of hospital
stay of 31 days.
The impact of AE status on hospital length of stay did not
differ by preventability status. The hazard ratios for pre-
ventable and non-preventable AEs on hospital length of
stay were essentially equivalent (HR = 0.46, 95% CI: 0.23–
0.91 versus HR 0.54, 95% CI: 0.30–1.0, respectively).
Discussion
Our study has three major findings. First, it confirms that
ICU patients face a high risk of treatment related injury.
Close to 20% of the patients in our study experienced an
AE while in the ICU and one in five AEs was considered
preventable. Second, we quantified the impact that ICU-
Table 1: Study patient characteristics
Characteristics N = 207
Female 75 (36%)
Median Age (25th – 75th %ile) 66 (54 – 75)
Median Glasgow Coma Scale (25th – 75th %ile) 8 (6 – 11)
Median Probability of Death (25th – 75th %ile)* 31 (13 – 62)
Charlson Index
0 62 (30%)
1 92 (44%)
2 39 (19%)
3 14 (7%)
Admitting Service
Medicine 86 (42%)
Surgery 121 (58%)
Diabetes
without end organ damage 19 (9%)
with end organ damage 9 (4%)
Indication for ICU admission
Medical 131 (63%)
Post operative (scheduled) 33 (16%)
Post operative (unscheduled) 19 (9%)
Trauma 24 (12%)
Ventilation required in first ICU day 160 (81%)
Location prior to ICU admission
ER 79 (38%)
OR 60 (29%)
Hospital floor 31 (15%)
Outside hospital 19 (9%)
Intermediate care unit 11 (5%)
Other 7 (3%)
*Probability of death calculated according to the New Simplified 
Acute Physiology Score [7].
Intermediate care = Medical and surgical step down units and the 
Post-anaesthetic care unit. Unless otherwise indicated, the number 
and percentage of patients with characteristic is presented.BMC Health Services Research 2008, 8:259 http://www.biomedcentral.com/1472-6963/8/259
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based AEs have on patients and the health system. We esti-
mated that AEs were independently associated with an
average increase in hospital length of stay of 31 days. This
association was similar in magnitude and significance for
preventable and non-preventable AEs. We did not find a
significant statistical association of AEs and mortality.
Third, we described the types of AEs that affect ICU
patients. In doing so, we found several classes of AEs and
preventable AEs. Not one of these classes represented
more than a third of all AEs.
This study reaffirms the importance of improving patient
safety in the ICU by measuring the risk of AEs and more
accurately quantifying their impact. Rothschild et. al. used
a surveillance protocol similar to ours and found that
20% of ICU patients had an AE [10]. In this study, how-
ever, patient outcomes were known when the AEs clinical
impact was rated. The investigators rated AEs in terms of
their clinical impact: 'significant', 'severe', 'life-threaten-
ing', or 'fatal. While such a rating scheme is descriptive, it
does not inform regarding downstream impact of the AEs.
Table 2: Adverse event types
Type All AEs n (%) Preventable AEs, n (%)* Non-preventable AEs, n (%)
Total 56 (100) 23 (100) 33 (100)
Procedural complication 18 (32) 6 (26) 12 (36)
Nosocomial infection 13 (23) 8 (35) 5 (15)
Adverse drug event 12 (21) 2 (9) 10 (30)
Surgical complication 6 (11) 0 (0) 6 (18)
Therapeutic error 5 (9) 5 (22) 0 (0)
System error 1 (2) 1 (4) 0 (0)
Diagnostic error 1 (2) 1 (4) 0 (0)
AE = adverse event. Non-preventable AEs were deemed unavoidable by the multidisciplinary review panel.
Table 3: Characteristics of patients by adverse event status
Characteristics Patients with AE Patients without AE P value
N4 0 1 6 7
Female – no. (%) 17 (42.5) 58 (34.7) 0.36
age – median yr. (25th – 75th %ile) 65 (53–75) 66 (55–76) 0.61
Glasgow coma scale – median (25th – 75th %ile) 7 (5–10) 8 (6–11) 0.07
Probability of death – median % (25th – 75th %ile)* 0.34 (0.17–0.70) 0.31 (0.12–0.62 0.45
Charlson Index – no. (%) 0.49
0 11 (27.5) 51 (30.5)
1 18 (45.0) 74 (44.3)
2 10 (25.0) 29 (17.4)
3 1 (2.5) 13 (7.8)
Admitting Service – no. (%) 0.76
Medicine 15 (37.5) 71 (42.5)
Surgery 25 (62.5) 96 (62.5)
Diabetes – no. (%) 0.16
without end organ damage 1 (2.5) 18 (10.8)
With end organ damage 3 (7.5) 6 (3.6)
Indication for ICU admission – no. (%) 0.09
Medical reasons 21 (52.5) 110 (65.9)
Post-op (scheduled) 5 (12.5) 28 (16.8)
Trauma 7 (17.5) 17 (10.2)
Post-op (unscheduled) 7 (17.5) 12 (7.2)
Ventilation required in first 24 hrs – no. (%) 36 (90) 131 (78.4) 0.09
Location prior to ICU admission – no. (%) 0.70
Emergency department 14 (35) 65 (38.9)
Operating room 11 (18.3) 49 (29.3)
Hospital floor 7 (17.5) 24 (14.4)
Outside hospital 3 (7.5) 16 (9.6)
Other 3 (7.5) 4 (2.4)
Intermediate care 2 (5.0) 9 (5.4)
*Probability of death calculated according to the New Simplified Acute Physiology Score [7].
ICU = Intensive Care Unit; AE = Adverse event; Intermediate care = Medical and surgical step down units and the Post-anaesthetic care unit.BMC Health Services Research 2008, 8:259 http://www.biomedcentral.com/1472-6963/8/259
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Furthermore, it does not help us to separate out the sever-
ity of the patient's underlying illness from the contribu-
tion by the AE. Finally, this methodology is potentially
biased because the reviewer may be influenced by patient
outcome [5,10]. These issues did not influence our study
as much because the outcomes of interest were objective,
precisely defined, and ascertained independent of the AE
rating. (Note that only two patients died at the time of our
rating. Otherwise all outcomes occurred after the review.)
We believe that our study adds to the AE literature by pro-
viding a more valid and quantifiable estimate of AEs
impact on patient outcomes.
Our results highlight the challenge faced by researchers
trying to demonstrate measurable improvements in
patient safety. Like Rothschild et. al. [10], we found sev-
eral diverse types of preventable AEs. This diversity sug-
gests that one single patient safety intervention is unlikely
to effectively reduce all preventable AEs, especially since
most quality improvement interventions have, at best, a
modest impact on outcomes [17,18].
Our study is consistent with other studies showing that
AEs predict an increased length of stay [19-23]. These
prior studies differed from ours in several important ways:
they evaluated patients not representative of adults in
North American ICUs; they used different methodologies
to capture information on complications; and, they did
not perform survival analyses, which accounted for the
time dependant nature of AEs. Nevertheless, the consist-
ent findings strengthen our assertion that there is a need
to find ways to reduce ICU-based AEs.
The methods we used were rigorous and defendable. We
chose to study ICU patients, who have been previously
demonstrated to be at high risk of AEs [10]. Therefore,
studying them offered us a relatively efficient way to study
this question. Our prospective design ensured that we
could identify important covariates for all patients in an
unbiased fashion and ensure a more accurate AE detection
than previous studies. We excluded AEs occurring prior to
ICU admission, as we did not have resources to perform
surveillance on all hospitalized patients. However, we
adjusted for time in hospital before ICU admission in our
model. Our outcomes were objective and were ascertained
independently of AE determination. Finally, we used
appropriate analytic methods to account for important
confounding variables and the time-dependent nature of
AEs [24].
Our study has several limitations. First, we studied ICU
patients only. Due to the critical condition of these
patients and their aggressive monitoring and treatment,
one might expect the effects of AEs to be greater in this
population. Thus, we might find a diminished association
between AEs and outcomes if we studied patients treated
in other areas of the hospital. Second, our secondary out-
come, length of stay, is not entirely patient-centered.
Other outcomes such as pain, anxiety or functional status,
which may be more sensitive to the effect of AEs and pre-
ventable AEs, might be more relevant to patients. We
chose not to study these outcomes as they are more diffi-
cult to reliably measure in an objective manner, especially
in critically ill patients. Furthermore, an increase in length
of stay is important from a patient perspective as it is often
necessitated for treatment of debilitating and painful con-
ditions. Third, as previously mentioned, we had a rela-
tively small sample size, increasing the possibility that we
Table 4: Effect of adverse events (AE) on patient outcomes.
a) Effect of AEs on time to death
Variable Hazard ratio (95% CI)
Model 1
AE 0.93 (0.44–1.98)
Age 1.0 (0.98–1.02)
Probability of death 1.41 (1.24–1.60)
LOS prior to ICU admit 0.94 (0.86–1.02)
Charlson score 1.13 (0.96–1.32)
Model 2*
Preventable AE 0.72 (0.25–2.04)
Non-preventable AE 0.69 (0.27–1.76)
CI = Confidence interval.
b) Effect of AEs on time to discharge and length of stay
Variable Hazard ratio (95% CI)
Model 1:
AE 0.50 (0.31–0.81)
Age 1.00 (0.99–1.01)
Probability of death 0.84 (0.78–0.91)
LOS prior to ICU admit 0.99 (0.96–1.02)
Charlson score 0.88 (0.77–1.00)
Model 2*:
Preventable AE 0.46 (0.23–0.91)
Non-preventable AE 0.54 (0.30–1.00)
CI = Confidence interval.
These tables present the association of ICU-based adverse events 
(AEs) with time to death (section a) and time to hospital discharge 
(section b). For each outcome, two models are presented: in model 1 
we modelled time to first AE as the independent variable of interest; 
in model 2 we modelled time to first preventable AE and non-
preventable AEs as the independent variables of interest. In all 
models, adverse events were expressed as time-dependent factors. 
All models were stratified by patient location prior to ICU admission. 
For brevity, we omitted the hazard ratios for these covariates for 
Model 2 from the table as they do not differ from the estimates 
presented for Model 1. The hazard ratio for probability of death 
represents the increase in risk expected with a 10% increase in the 
new Simplified Acute Physiology Score [7].BMC Health Services Research 2008, 8:259 http://www.biomedcentral.com/1472-6963/8/259
Page 7 of 8
(page number not for citation purposes)
failed to detect true associations between preventable AEs
and important outcomes. Fourth, some of the reviewers
were participating in some patient care responsibilities
indirectly, as they were considered back-up providers.
Although this might lead to a propensity to avoid rating
cases of errors, we do not feel this occurred. Furthermore,
this potential bias would not influence the measured
association of the AEs with length of stay and mortality.
Conclusion
In conclusion, ICU-based AEs are common and have a
large impact on hospital length of stay. Reducing their
impact will be challenging because preventable AEs are
less common and have many different causes. These data
suggest that efforts to improve outcomes for ICU patients
might be more effective if they focus on new technologies
and treatment methods rather than focusing on error
reducing strategies exclusively.
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